SuperworthARS Pharmaceuticals price to sales ratio SPRY
Market value divided by revenue over the last twelve months, since 2025.
- Today, Oct 23, 2026
- 3.4×
- Peer median
- 1.5×
ARS Pharmaceuticals' price to sales ratio is 3.4× as of Oct 23, 2026.
The median for 10 large drugmakers of a similar size is 1.5×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 3.4× | 3.4× | 10.3× |
| 2025 | 7.9× | 5.3× | 18.4× |
Against its peers
Companies in Drug Manufacturers - General nearest ARS Pharmaceuticals' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| SPRYARS Pharmaceuticals | 3.4× |
| ARVNArvinas | 1.5× |
| PBYIPuma Biotechnology | 2.5× |
| IRWDIronwood Pharmaceuticals | 1.5× |
| ZVRAZevra Therapeutics | 4.3× |
| CRMDCorMedix | 1.3× |
| COLLCollegium Pharmaceutical | 0.9× |
| NATRNatures Sunshine Products | 0.4× |
| ABUSArbutus Biopharma | 4.6× |
| AMPHAmphastar Pharmaceuticals | 1.5× |
| OMEROmeros | n/m |
| Peer median | 1.5× |
Where ARS Pharmaceuticals ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on ARS Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.